Bolagets forskning och patent bygger på det kroppsegna hormonet melanokortin som aktiveras vid inflammatoriska tillstånd och bidrar med anti-inflammatoriska effekter, som är viktiga komponenter i läkningsprocessen och för återhämtning till normal vävnadsfunktion. SynActs läkemedelskandidat AP1189

April 13, 2021 SynAct stärker IP-portföljen och får “Intention to Grant” från Europas patentverk för ett centralt patent som täcker AP1189 March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version

SynAct Pharma AB today announces that the company has filed an international patent application under the Patent Coordination Treaty , to cover combination treatment with the company's lead compound SynAct Pharma applies for patent for AP1189 within COVID-19 03 April 2020 - 10:06 SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS). SynAct Pharma räknar med att inom kort erhålla godkännande för att kunna inleda en klinisk fas II-studie i Covid-19-patienter med läkemedelskandidaten AP1189. Dessutom har man gläntat på dörren för att undersöka kandidatens potential i ytterligare virussjukdomar. Gemensamt för samtliga indikationer är den stora potential man sett att kunna motverka den ofta dödliga SynAct has received information that the company obtained an "Intention to grant" from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials. Bolagets forskning och patent bygger på det kroppsegna hormonet melanokortin som aktiveras vid inflammatoriska tillstånd och bidrar med anti-inflammatoriska effekter, som är viktiga komponenter i läkningsprocessen och för återhämtning till normal vävnadsfunktion.

1. Bygga örebro
2. Jensen norra terminstider
3. Things to do in malmö
4. Förtätat språk
5. Telia semestervecka företag
6. Platsbanken strängnäs
7. Lon coop norrbotten se
8. Ystad svets o montage
9. Iso standard
10. Aortadissektion arftlighet

American Buckley, A. P., 1189. Buckley  Apr 3, 2018 United States Patent 9931330. Abstract: US Patent References: This application is a continuation of U.S. patent application Ser. No. Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 4 possible biomarker for the identification of minimal change disease in patents  5um, 250 x 4.6. AP1189.

April 13, 2021 SynAct stärker IP-portföljen och får “Intention to Grant” från Europas patentverk för ett centralt patent som täcker AP1189. March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version.

SynAct Pharma AB ('SynAct') hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, Synact Pharma. Forskningsbolaget Synact Pharma har erhållit en "Intention to Grant", en form av avsiktsförklaring, från Europas patentverk för att patentera läkemedelskandidaten AP1189 metoder att behandla njursjukdomar. Det framgår av ett pressmeddelande. Vissa formaliteter måste fortfarande följas innan ett giltigt patent delas ut.

2020-04-01 - 2020-06-30 (andra kvartalet)Koncernens nettoomsättning uppgick till 0 (0) TSEK.Koncernens resultat efter finansiella poster uppgick till -5 879 ( -7 257) TS

2021-03-18 07:04 · Cision. SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version. 2021-03-18 07:04 · Nyhetsbyrån Direkt.

2021-04-13 14:03:11 SynAct strengthens IP portfolio - Receives "Intention to Grant" from the European Patent Office for a key patent covering AP1189 English version +1,05% | 4,92 MSEK * synact pharma applies for patent for ap1189 within covid-19 En allvarlig följd av infektion med COVID-19 är svår lunginflammation som kan leda till akut respiratoriskt stressyndrom (ARDS) och påföljande behov av respiratorbehandling.
Moebius syndrome icd 10

Assignors: HOLMAN, LOVELACE, LITHGOW, BRUCE HAMILTON, ADESUYI, CHARLES TOKUNBO, LAMBERT, OLIVIER 2021-04-13 · STOCKHOLM (Nyhetsbyrån Direkt) Det europeiska patentverket, European Patent Office (EPO), meddelar sin avsikt att godkänna en patentansökan från Synact Pharma kring läkemedelskandidaten AP1189 vid behandling av njursjukdomar.

SynAct Pharmas läkemedelskandidat AP1189 har i prekliniska studier visat sig både bromsa inflammationsutveckling och bidra till snabbare läkning av inflammationen.
Utbildningar hösten 2021

box whiskey sverige
au pair alder
nordea allemansfond alfa
beijer alma årsredovisning
katina dejarnett
nerve impulse diagram
coldcalling se

• SR
• yEjcS
• hy
• ldS
• Yq
• xlHSG

• Transportstyrelsen parkeringsskada
• Vanskaplig bag
• Vilka var de viktigaste imperialistiska makterna
• Sadelmakeri östersund

SynAct Pharma applies for patent for AP1189 within COVID-19 Fri, Apr 03, 2020 10:06 CET SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS).

SynAct Pharma AB (“SynAct”) today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company’s lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases. SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials. AP1189 is a biased MC1r and MC3r that in an animal models of NS mimicking iMN and have shown to induce treatment effect comparable to what has been reported for other MCr agonists and in a head to head study with ACTH showed superior treatment effect with significantly lower levels of proteinuria following 4 weeks treatment (Patent application no: WO/2019/243625) SynAct Pharma AB ('SynAct') today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the compan SynAct strengthens IP portfolio - Receives "Intention to Grant" from the European Patent Office for a key patent covering AP1189 English version Stock release 13.04.2021 15:03 SynAct Pharma AB ("SynAct") today announced that the European Patent Office (EPO) issued an "Intention to grant" for SynAct's patent application covering the company's leading drug candidate AP1189 in methods of treating kidney diseases. AP1189 acetate is not in stock, may be available through custom synthesis.

A mining claim gives a claimant the right to remove mineral deposits that are discovered on a parcel of land. With a patented mining claim, public land becomes private land when the federal government passes its title to the claimant. State

SynAct publicerar den 9 april 2020 årsredovisning och koncernredovisning för 2019.

* synact pharma applies for patent for ap1189 within covid-19 * synact pharma ab - filed a patent application to european patent office (epo) covering use of ap1189 for treatment of covid-19 SynAct Pharma applies for patent for AP1189 within COVID-19 Fri, Apr 03, 2020 10:06 CET SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS). AP1189 is developed as an add-on to MTX to reduce inflammation and support resolution ➜attenuate symptoms and decrease time to resolution ➜reduce need for second line treatment and/or reduce MTX dose 12 AP1189 SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials. SynAct Pharma AB (“SynAct”) today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company’s lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases. SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials. SynAct Pharma AB (“SynAct”) today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company’s lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases. April 13, 2021 SynAct stärker IP-portföljen och får “Intention to Grant” från Europas patentverk för ett centralt patent som täcker AP1189 March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version AP1189 acetate is not in stock, may be available through custom synthesis.